Ibex LTD

IBEX Limited has announced a new share repurchase program authorizing the buyback of up to $20 million of its common stock over the next 12 months.

IBEX Limited announced record third fiscal quarter revenue of $164.4 million, a 17% increase year-over-year, and raised its full-year revenue and Adjusted EBITDA guidance.

IBEX Limited announced record second fiscal quarter revenue and EPS, driven by strong growth in key verticals and offshore regions, leading to an upward revision of its full-year guidance.

IBEX Limited announced the appointment of Shuja Keen to its Board of Directors and significant enhancements to its corporate governance structure, including a new Lead Independent Director.

IBEX Limited shareholders approved key proposals at their 2025 annual general meeting, including setting the board size, electing directors, and amending the long-term incentive plan.

IBEX Limited has established a formal Nominating Committee to address corporate governance concerns raised by institutional shareholder advisory firms.

IBEX Limited announced a 16.8% year-over-year revenue increase for the third quarter of fiscal year 2026, driven by growth in key verticals and digital acquisition services.

IBEX Limited announced robust financial results for the quarter and six months ended December 31, 2025, driven by revenue growth and improved profitability.

IBEX Limited reports strong first-quarter fiscal 2026 results with significant revenue and net income growth driven by offshore expansion and digital solutions.

Ibex Limited announces an 11.0% increase in revenue for the three months ended March 31, 2025, driven by growth in HealthTech, Travel, Retail, and other sectors.

IBEX Limited announces a 6.1% increase in revenue for the quarter ended December 31, 2024, driven by growth in HealthTech, Travel, Transportation & Logistics, and Retail & E-commerce verticals.

IBEX Limited announced a 4.1% increase in revenue for the quarter ended September 30, 2024, reaching $129.7 million, driven by growth in the HealthTech, Retail & E-commerce, and Travel, Transportation & Logistics sectors.

IBEX Limited announced robust financial results for fiscal year 2025, with revenue increasing 9.8% to $558.3 million and diluted EPS rising to $2.36, fueled by growth in digital-first and offshore operations.

Ibex Limited's fiscal year 2024 results show a slight revenue decrease but improved net income, reflecting strategic shifts and market challenges.

Fiona Elizabeth Beck, a Director of IBEX Ltd, received 1,252 shares of common stock on July 31, 2026.

Mingzhe Zhuang, a Director of IBEX Ltd, received 1,252 shares of common stock on July 31, 2026.

John William Jones, a Director of IBEX Ltd, received 1,353 shares of common stock on July 31, 2026.

Bruce Neil Dawson, Chief Sales and CS Officer of IBEX Ltd, reported multiple transactions in common stock on July 31, 2026.

Taylor C Greenwald, Chief Financial Officer of IBEX Ltd, reported multiple transactions in common stock on July 31, 2026.

Paul Joseph Inson, Chief People Officer of IBEX Ltd, reported multiple transactions in common stock on July 31, 2026.

Ibex Limited announced that director Mohammed Khaishgi has withdrawn his nomination for re-election for personal reasons, creating a board vacancy.

IBEX Limited's Board of Directors has approved a shift to a simple majority vote for Bye-Laws amendments, addressing shareholder feedback and governance concerns.

IBEX Limited has established a formal Nominating Committee to address shareholder concerns and enhance its corporate governance structure.

IBEX Limited's 2025 proxy statement details strong financial growth, a shift from controlled company status, and proposals for its Annual General Meeting.

IBEX Limited announces its 2024 Annual General Meeting of Shareholders to be held on December 5, 2024, featuring proposals for director appointments, auditor ratification, and setting the number of directors.

PineBridge Global Emerging Markets Partners II, L.P. and its affiliates have significantly reduced their beneficial ownership in IBEX Ltd, falling below the 5% reporting threshold as of February 26, 2025.

PineBridge Global Emerging Markets Partners II, L.P. and its affiliates have filed an Amendment No. 6 to their Schedule 13D, reporting a reduced beneficial ownership of 8.3% in IBEX Ltd following a series of share sales in January and February 2025.

PineBridge Global Emerging Markets Partners II, L.P. and related entities have filed an Amendment No. 5 to their Schedule 13D, disclosing a reduction in their beneficial ownership of IBEX Ltd common shares to 9.5% following a series of open market sales.

American Century Investment Management has filed a Schedule 13G reporting a 5.1% beneficial ownership stake in IBEX Limited.

American Century Capital Portfolios, Inc., American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have filed an Amendment No. 5 to their Schedule 13G, reporting beneficial ownership of 4.4% of IBEX Limited's Common Stock.

JPMorgan Chase & Co. has filed an amended Schedule 13G, disclosing a 2.9% beneficial ownership stake in IBEX LIMITED as of April 30, 2025.

JPMorgan Chase & Co. has reported a 5.1% beneficial ownership stake in IBEX LIMITED, primarily through its banking and investment management subsidiaries.

American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have jointly reported a 5.6% beneficial ownership stake in IBEX Limited as of December 31, 2024.